Trial Profile
A Phase I Dose Escalation Study of MK1496 in Patients With Advanced Solid Tumor
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs MK 1496 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 25 Oct 2012 Actual end date changed from Dec 2010 to Jan 2011 as reported by ClinicalTrials.gov.
- 11 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Feb 2011 Actual end date changed from Jun 2011 to Dec 2010 as reported by ClinicalTrials.gov.